2024 exceptional surveillance of psoriasis: assessment and management (NICE guideline CG153)

In July 2024, we reviewed this guideline in response to a price decrease of the combined calcipotriol monohydrate and betamethasone dipropionate product.

Surveillance decision

We plan to update guidance on topical treatment of psoriasis affecting the trunk and limbs in line with a price decrease affecting combined calcipotriol monohydrate and betamethasone dipropionate.

More information is available on the web page for NICE’s prioritisation decisions.

This page was last updated: 11 July 2024